PMR is no a disease of vague shoulder and hip pain. It's something much more specific: a chronic inflammatory disease of musculotendinous structures. We're starting to understand the real story. @drceowen lays it out for #ACR22 this morning @EBRheum @SattuiSEMD @RheumNow https://t.co/thqtCwSULM

Bimekizumab (BKZ) in AxSpA to Wk52 ◦ sustained efficacy ◦ suppression of inflammation ◦ improvements in function and quality of life ◦ no new safety signals were observed ◦ consistent with the safety profileWk24 data Baraliakos #L14 https://t.co/gk23g4vqQl #ACR22 @RheumNow

Fernandes et al. CPPD assoc increased nephrolithiasis. 8.06% vs 4.88%; p<0.0001. @RheumNow #ACR22 Abstr#1819 https://t.co/o8Afmcc429 https://t.co/3EoOXpqpGN

Chen et al. Appendicitis associated increased risk incident SLE in population-based case-control study from Taiwan. HR 2.04 @RheumNow #ACR22 Abstr#1750 https://t.co/L9dTpMdHNP https://t.co/mEHeL6JnuE

Parperis et al. Cypriot population based study. ACS in CPPD assoc longer LOS, and increased mortality 6.9% vs 5.6% (p<0.001). @RheumNow #ACR22 Abstr#1817 https://t.co/uWv67aZa9L https://t.co/3oRFXREcYx

Helget et al. Subanalysis of STOP Gout. Allopurinol and febuxostat equal efficacy in CKD 3. More AKI with allopurinol 8.3% vs 2.4%. @RheumNow #ACR22 Abstr#1829 https://t.co/Z4JqYp4mTT https://t.co/xd8VGJVkNo

Low dose #glucocorticoids in rheumatic diseases can lower bone mass and increase # even 2.5 mg #prednisone. The change in #BMD was more predictive of fracture not absolute BMD. L01 #ACR22 #ACRBest @RheumNow https://t.co/MbTk0L4DoK

Mortality in patients with SpA Abstract #0569 #ACR22 @RheumNow ✏️systematic review/meta-analysis of 19 studies ✋No increased mortality in patients with PsA compared to gen. pop. 🦠Infection, 🫀CV, and 🫁 pulm. specific mortality sig. higher in PsA patients

How do we know what PMR is all about? Imaging has helped enormously, and every step of the way, imaging has got better and better. Specific findings which reveal the culpable pathology. @drceowen #ACR22 @RheumNow https://t.co/4OOOk0F3jW

NSAIDs and CV risk in Inflammatory Arthritis Dr. Richard Conway discusses abstract 1207, being presented #ACR22 meeting. https://t.co/CjU2YbA3tk https://t.co/bHE4xw2IRF